Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT00095940 · ClinicalTrials.gov registry record · Phase 1
Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors
A Phase 1 study of Recurrent Childhood Ependymoma and Recurrent Childhood Medulloblastoma, sponsored by National Cancer Institute (NCI).
- Completed
- Registry status
- Phase 1
- Development phase
- 52
- Enrollment target
- 1
- Study location
NCT00095940 is a Phase 1 study of Recurrent Childhood Ependymoma and Recurrent Childhood Medulloblastoma that has completed, run by National Cancer Institute (NCI). The registered enrollment target is 52 participants, above the 34-participant average among 4 other Recurrent Childhood Ependymoma trials with a reported enrollment target (53% higher). The trial reports 1 study location across 1 state.
The verdict
NCT00095940, a Phase 1 study of Recurrent Childhood Ependymoma and Recurrent Childhood Medulloblastoma, has completed, sponsored by National Cancer Institute (NCI).
- COMPLETED
- Registry status
- Phase 1
- Development phase
- 52 participants
- Enrollment target
- 1
- Study location
Study Summary
This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
Conditions Studied
Interventions
- OTHER laboratory biomarker analysis
- PROCEDURE therapeutic conventional surgery
- OTHER pharmacological study
- PROCEDURE positron emission tomography
- DRUG lapatinib ditosylate
Study Locations (1)
Tennessee
- Pediatric Brain Tumor Consortium - Memphis
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 52 participants |
| Start Date | 2004-10 |
| Est. Completion | 2010-07 |
| Phase | Phase 1 |
Interested in This Trial?
Full Details on ClinicalTrials.gov ↗What the Registry Record Tells You About NCT00095940
The ClinicalTrials.gov registry entry for NCT00095940 describes a study currently listed as completed, categorized as Phase 1. The registered enrollment target is 52 participants, a figure that helps gauge the scale of data the investigators plan to collect, above the 34-participant average among 4 other Recurrent Childhood Ependymoma trials with a reported enrollment target (53% higher). The listed sponsor is National Cancer Institute (NCI), which has 3,257 total studies on file at ClinicalTrials.gov.
The record links to 8 conditions, with Recurrent Childhood Ependymoma appearing as the primary indexed condition, and to 5 interventions - of which laboratory biomarker analysis is the first listed.
NCT00095940 reports 1 study location spanning 1 distinct geographic area - top geographies include Tennessee.
Frequently Asked Questions
What is clinical trial NCT00095940 about?
NCT00095940 is a clinical study titled "Lapatinib in Treating Young Patients With Recurrent or Refractory Central Nervous System Tumors". This phase I/II trial studies lapatinib to see how well it works in treating young patients with recurrent or refractory central nervous system (CNS) tumors. Lapatinib may stop the growth of tumor cells by blocking the enzymes necessary for their growth.
What is the current status of trial NCT00095940?
This trial is currently completed. It is a Phase 1 study. The enrollment target is 52 participants. The study started on 2004-10. Estimated completion is 2010-07.
What conditions does trial NCT00095940 study?
This clinical trial studies the following conditions: Recurrent Childhood Ependymoma, Recurrent Childhood Medulloblastoma, Recurrent Childhood Brain Stem Glioma, Recurrent Childhood Glioblastoma, Recurrent Childhood Anaplastic Astrocytoma.
What interventions are being tested in trial NCT00095940?
The interventions under investigation include: laboratory biomarker analysis (OTHER), therapeutic conventional surgery (PROCEDURE), pharmacological study (OTHER), positron emission tomography (PROCEDURE), lapatinib ditosylate (DRUG).
Who is sponsoring clinical trial NCT00095940?
This trial is sponsored by National Cancer Institute (NCI), which has 3,257 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT00095940 being conducted?
This trial has 1 study location across Tennessee. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Recurrent Childhood Ependymoma
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
-
Pembrolizumab in Treating Younger Patients With Recurrent, Progressive, or Refractory High-Grade Gliomas, Diffuse Intrinsic Pontine Gliomas, Hypermutated Brain Tumors, Ependymoma or Medulloblastoma
ACTIVE NOT RECRUITING · Phase 1
-
Ribociclib and Everolimus in Treating Children With Recurrent or Refractory Malignant Brain Tumors
COMPLETED · Phase 1
-
Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)
ACTIVE NOT RECRUITING · Phase 2
-
Palbociclib in Treating Patients With Relapsed or Refractory Rb Positive Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With Activating Alterations in Cell Cycle Genes (A Pediatric MATCH Treatment Trial)
COMPLETED · Phase 2
Explore more on PlainTrial
Recurrent Childhood Ependymoma
All registered trials for this condition
Recurrent Childhood Medulloblastoma
All registered trials for this condition
Tennessee
All trials with a study site in Tennessee
Recruiting now
Find trials open to new participants near you
Rankings
Top sponsors, conditions, and phases
Read our methodology - how this data is sourced, computed, and verified.
Related
Every figure on PlainTrial is rendered directly from the ClinicalTrials.gov registry, no number is typed in by an editor. This page mirrors this trial's own ClinicalTrials.gov registry record, live from the dataset. See our editorial standards & corrections policy, the methodology behind these numbers, or report a data error.